FACULTY
Kimberly Braxton Lloyd, PharmD
Associate Professor, Department of Pharmacy Practice
Clinical Director, Auburn University Pharmaceutical Care Center
Auburn University Harrison School of Pharmacy
Auburn, AL
Robert M. Naclerio, MD
Professor of Surgery
Section Chief, Otolaryngology–Head and Neck Surgery
University of Chicago Medical Center
Chicago, IL
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
| Name of Faculty or Presenter |
Reported Financial Relationship |
| Kimberly Braxton Lloyd, PharmD |
Advisory Board—Sanofi-Aventis |
| Robert M. Naclerio, MD |
Grant/Research Support—Capnia, |
| |
GlaxoSmithKline, Merck, Novartis, Schering |
| |
Consultant—Allux Medical, GlaxoSmithKline, |
| |
Merck, Schering |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
| Name of Planner or Manager |
Reported Financial Relationship |
| Linda Graham, RN, BSN, BA |
No real or apparent conflicts of interest to report. |
| Joseph Cupolo, MA, MS |
No real or apparent conflicts of interest to report. |
ACCREDITATION
STATEMENTS
Pharmacy
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Program No.: 430-000-08-001-H01-P; 430-000-08-001-H01-T
Credits: 2.0 hours (0.20 ceu)
Published: January 1, 2008
Expires: January 31, 2010
Media:
Monograph
Fee Information:
There is no fee for this educational program.
Estimated time to complete activity:
Estimated time to complete this program and posttest is 90 to 120 minutes.
Exam processing inquiries and booklet orders to:
CE Customer Service Manager (800) 825-4696
Direct educational content inquiries to:
CE Director (800) 331-9396
ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Postgraduate Healthcare Education, LLC. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credits.TM Physicians should only claim credit commensurate with the extent of their participation in the activity.
TARGET AUDIENCE
This accredited program is targeted to pharmacists, pharmacy technicians, nurse practioners, and physician assistants.
PROCEDURES
Please complete the posttest questions and program evaluation online at: www.powerpak.com (a username and password are required to access your account). Upon passing the exam with a score of 70% or better, you can print out your statement of credit immediately. You can also view your test history at any time and print out duplicate statements from the Web site.
GOAL
To review the etiology and clinical presentation of nasal congestion and provide strategies for its appropriate management.
EDUCATIONAL OBJECTIVES
After completing this program, participants will be able to:
- Review the etiologies and manifestations of nasal congestion;*
- Outline the current approaches to the management of nasal congestion;*
- Describe strategies for determining the most appropriate therapy for managing nasal congestion, including the need for uninterrupted sleep;*
- Explain the need for communication with patients;* and
- List strategies clinicians may employ to educate, counsel, and monitor their patients who present with nasal congestion.
*Also applies to pharmacy technicians.
Disclosure
of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Postgraduate Healthcare Education, LLC, and GlaxoSmithKline Consumer Healthcare. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education program have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer’s package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.
